Robert DeLuca
Orexo US, a subsidiary of Swedish specialty pharma company Orexo, has appointed Robert DeLuca as President.
Deluca has had leadership roles for a number of companies including Sanofi, Schering-Plough, Berlex, Pharmacia and most recently as Chief Commercial Officer at Archimedes Pharma.
“Establishing a commercial presence in the US is a key milestone towards the launch of Zubsolv and I am particularly pleased that we have succeeded in recruiting Mr. DeLuca to establish and lead our US subsidiary and the launch of Zubsolv,” – Orexo’s proprietary opioid dependence therapy - said CEO Nikolaj Sørensen.
“He brings extensive experience in establishing commercial operations in the US and his background in managed care will be a major asset to ensure a successful launch of Zubsolv.”